A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

An In Vitro Model for Studying Tau Aggregation Using Lentiviral-mediated Transduction of Human Neurons

5.7K views

DOI:

10.3791/59433

May 23rd, 2019

In This Article

Summary

This protocol details a procedure in which human neuronal cultures are transduced with lentiviral constructs coding for mutant human tau. Transduced cultures display tau aggregates and associated pathologies.

Abstract

Aberrant aggregation of the protein tau is pathogenically involved in a number of neurodegenerative diseases, including Alzheimer’s disease (AD). Although mouse models of tauopathy have provided a valuable resource for investigating the neurotoxic mechanisms of aggregated tau, it is becoming increasingly apparent that, due to interspecies differences in neurophysiology, the mouse brain is unsuitable for modeling the human condition. Advances in cell culture methods have made human neuronal cultures accessible for experimental use in vitro and have aided in the development of neurotherapeutics. However, despite the adaptation of human neuronal cell cultures, in vitro models of human tauopathy are not yet widely available. This protocol describes a cellular model of tau aggregation in which human neurons are transduced with lentiviral-derived vectors that code for pathogenically mutated tau fused to a yellow fluorescent protein (YFP) reporter. Transduced cultures produce tau aggregates that stain positively for thioflavin and display markers of neurotoxicity, such as decreased axonal length and increased lysosomal volume. This procedure may be a useful and cost-effective model for studying human tauopathies.

Introduction

Pathological aggregation of the microtubule-associated protein tau is a defining feature of many neurodegenerative diseases, including AD, frontotemporal dementia (FTD), Pick’s disease, and progressive supranuclear palsy (PSP)1. In a nondiseased state, tau binds to and stabilizes microtubule filaments in neuronal axons2. However, disease-associated hyperphosphorylation of tau promotes tau aggregation, dissociation from microtubules, and neuronal toxicity3. The toxic effects of aggregated tau may involve aberrant activation of cholinergic4 and glutamatergic receptors

Access restricted. Please log in or start a trial to view this content.

Protocol

1. Preparation of Media and Reagents

  1. Thaw the basement membrane matrix coating for culture plates at 4 °C (do not allow the basement membrane matrix to warm up or it will solidify). Make 1 mL aliquots and store them at -20 °C or -70 °C.
  2. Reconstitute basic fibroblast growth factor (bFGF) in sterile phosphate-buffered saline (PBS) at 10 µg/mL and make 10 µL aliquots. Store them at 4 °C.
  3. To a new, unopened, 500 mL bottle of DMEM/F12 with glutamine, add B27 (10 mL), N2 (5 mL), and penicillin-streptomycin (5 mL). Place 50 mL of this neural stem cell (NSC) media in a conical tube and add 10 µL of 10 µg/....

Access restricted. Please log in or start a trial to view this content.

Results

Tau-RDLM-YFP-transduced neurons were fluorescently tagged with YFP, and RDLM-transduced cultures displayed aggregates after transduction. These inclusions stained positive for thioflavin (Figure 1). As Figure 1 demonstrates, this protocol produces neuronal cultures that display thioflavin-positive tau aggregates. For initial experiments, it is recommended that neuronal differentiation is confirmed by immunolabeling the neuron-specific marker β-tubulin III in cul.......

Access restricted. Please log in or start a trial to view this content.

Discussion

This protocol describes the generation of an in vitro model of human tauopathy that exhibits silver-stain-positive aggregates and thioflavin-positive neurofibrillary tangles (NFTs). Moreover, transduced cells display tau-induced pathologies such as morphological defects, reduced synaptogenesis, and an increased lysosomal volume. The main advantage of this protocol is that it provides an accessible and cost-effective model of neuronal tauopathy, which can be used for drug screening studies, as well as for the analysis of .......

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors have nothing to disclose.

Acknowledgements

The authors would like to thank Dr. Peter Davies at Albert Einstein College of Medicine for supplying PHF-1 and CP13 antibodies and Dr. Marc Diamond at the University of Texas, Southwestern, for providing the tau constructs. This work was supported by grants from the Alzheimer’s Association (NIRG-14-322164) to S.H.Y. and from the California Institute for Regenerative Medicine (TB1-01193) to P.R.

....

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
10 cm culture dishesThermofisher12556002
15 mL tubesBiopioneerCNT-15
16% paraformaldehydeThermofisher50-980-487
24 well culture platesThermofisher930186
50 mL tubesBiopioneerCNT-50
70% ethanol in spray bottleVarious sourcesNA
B27 supplementThermofisher17504044
Basement membrane matrix (Matrigel)Corning356231
Basic FGFBiopioneerHRP-0011
Bovine serum albuminSigmaA7906
Cell culture incubatorVarious sourcesNA
CentrifugeVarious sourcesNA
DMEM-F12 culture media with glutamineThermofisher10565042
Ethanol (50% concentration or higher)Various sourcesNA
Flourescently labeled secondary antibodiesVarious Sources, experiment dependentNA
Fluorescent microscopeVarious sourcesNA
Glass coverslipsThermofisher1254581
Glass slidesThermofisher12-550-15
Human neural stem cellsVarious sourcesNA
Lentiviral vectorsVarious sourcescustom order
Mounting mediaThermofisherP36934
N2 supplementThermofisher17502048
Penicillin-StreptomycinThermofisher15140122
Phosphate buffered salineThermofisher14190250
Primary antibodiesVarious Sources, experiment dependentNA
Rocking or rotating platformVarious sourcesNA
Sterile cell culture hoodVarious sourcesNA
Thioflavin SSigmaT1892-25G
Triton X-100ThermofisherBP151-100
Water bathVarious sourcesNA

References

  1. Rojas, J. C., Boxer, A. L. Neurodegenerative disease in 2015: Targeting tauopathies for therapeutic translation. Nature Reviews Neurology. 12 (2), 74-76 (2016).
  2. Kadavath, H., et al.

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Tags

Lentiviral TransductionFluorescent MicroscopyThioflavin StainingAxonal DegenerationLysosomal VolumeBeta tubulin IIINeuronal DifferentiationCell Culture Media